If you’re a Parkinson’s veteran, what would you tell a rookie? If you’re a rookie, what Parkinson’s lessons would you like to learn? I was diagnosed in late 2014 with young-onset Parkinson’s disease at the
Parkinsons Articles
Dosing Starts in Canada in Trial of DA01 for Advanced Parkinson’s
A first patient in Canada has been dosed in a Phase 1 clinical trial of DA01, a cell-based investigational therapy for advanced Parkinson’s disease by BlueRock Therapeutics. The therapy consists of surgically injecting neurons (nerve cells) that
FDA Allows Yumanity to Test Single Doses of YTX-7739
The U.S. Food and Drug Administration (FDA) has issued a partial clinical hold in response to an application by Yumanity Therapeutics requesting permission to begin clinical testing in the U.S. of YTX-7739 for Parkinson’s disease.
Sanofi, ABL Bio Join to Develop ABL301 as Potential Treatment
ABL Bio and Sanofi are working under a global licensing agreement to jointly develop ABL301 — an investigational bispecific antibody targeting both alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R) — in possibly treating Parkinson’s disease. Under
Pilot Trial of FGF-1 to Promote Blood Vessel Growth in Brain Planned
Zhittya Genesis Medicine plans to launch what it is calling a “Compassionate Use Clinical Trial” of FGF-1, a biological compound aiming to stimulate new blood vessel growth in the brain, for people with mild-to-moderately severe Parkinson’s disease.
A Caregiver’s Role in the ‘TBM’ Support Partnership
As this chronic illness progression continues to steal away functioning, I need more support. When I previously wrote about the excellent role Mrs. Dr. C plays within the support partnership, a reader asked, “How do
Satisfaction and Interest Strong for Remote Trials, Study Finds
People who took part in remote, video-conducted clinical trials for Parkinson’s disease reported high levels of satisfaction and interest in participating in future studies with remote video visits, scientists report. Three such trials showed that
1st Patient Dosed in Trial of UB-312, Vaccine Against Protein Clumps
A first patient with Parkinson’s disease has been dosed with UB-312, Vaxxinity’s experimental vaccine therapy targeting alpha-synuclein, after treatment safety and tolerability was seen in healthy volunteers in a clinical trial. This marks the beginning of
$500,000 Fox Foundation Grant Goes to Yumanity’s YTX-7739 Research
Yumanity Therapeutics has been awarded a $500,000 research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help accelerate testing of an investigational Parkinson’s disease therapy, YTX-7739. “MJFF is a globally recognized
2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinson’s Progression
Biogen and Denali Therapeutics are planning to launch two late-stage clinical trials to further evaluate the potential of their investigational oral therapy BIIB122/DNL151 in treating people with Parkinson’s disease. The Phase 3 and Phase 2b trials, expected to
How Aquatic Therapy Can Benefit People With Parkinson’s Disease
Spending time in the water can be refreshing, relaxing, and healing for both the body and the soul. For those with Parkinson’s disease (PD), performing exercises or movements in the water, a practice known as
Psychosis Common With Late-stage Parkinson’s, Study Reports
Psychosis, including hallucinations and delusions, is frequent in people with late-stage Parkinson’s disease a study reported, after psychotic symptoms were confirmed in more than half of the 92 patients examined. Some degree of cognitive impairment was